TABLE 5.
Detailed information of the 4 deaths.
| case | Sex | Age | Suspected drug | Time a (day) | Diseases | Dosage | ADR |
|---|---|---|---|---|---|---|---|
| 1 | Male | 60 | RHIL-2 | 2 | Kidney malignant tumor | 3 million U | Anaphylactoid reaction |
| 2 | Male | 73 | Gefitinib | 58 | Respiratory failure; lung carcinoma | 250 mg | Pulmonary fibrosis |
| Coronary atherosclerosis; diabetes; hypoproteinemia | |||||||
| 3 | Female | 48 | Regorafenib | 19 | Colonic adenocarcinoma; hepatic metastasis | 160 mg | Hypertension; high aminotransferas |
| 4 | Female | 69 | Gefitinib | 10 | Esophageal carcinoma; lung carcinoma | 250 mg | Pneumonia |
a
The occurrence time of the ADRs.